1. The IQVIA Institute, Biosimilars in the United States 2020–2024; 2020. https://www.iqvia.com/insights/the-iqvia-institute/reports/biosimilars-in-the-united-states-2020-2024.
2. Gottlieb S. Remarks from FDA Commissioner Scott Gottlieb, M.D., as prepared for delivery at the Brookings Institution on the release of the FDA’s Biosimilars Action Plan; 2018. https://www.fda.gov/news-events/press-announcements/remarks-fda-commissioner-scott-gottlieb-md-prepared-delivery-brookings-institution-release-fdas.
3. Mulcahy AW, Hlavka JP, Case SR. Biosimilar cost savings in the United States: initial experience and future potential. Rand Health Q. 2018;7(4):3.
4. Yang J, et al. Does biosimilar bevacizumab offer affordable treatment options for cancer patients in the USA? A budget impact analysis from US commercial and medicare payer perspectives. Appl Health Econ Health Policy. 2021;19:605–18.
5. U.S. Food and Drug Administration, FDA-Approved Biosimilar Products. U.S. Food & Drug Administration (2020). https://www.fda.gov/drugs/biosimilars/biosimilar-product-information.